Metformin Increases Sensitivity of Pancreatic Cancer Cells to Gemcitabine by Reducing CD133(+) Cell Populations and Suppressing ERK/P70S6K Signaling

The prognosis of pancreatic cancer remains dismal, with little advance in chemotherapy because of its high frequency of chemoresistance. Metformin is widely used to treat type II diabetes, and was shown recently to inhibit pancreatic cancer stem cell proliferation. In the present study, we investiga...

Descripción completa

Detalles Bibliográficos
Autores principales: Chai, Xinqun, Chu, Hongpeng, Yang, Xuan, Meng, Yuanpu, Shi, Pengfei, Gou, Shanmiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4585731/
https://www.ncbi.nlm.nih.gov/pubmed/26391180
http://dx.doi.org/10.1038/srep14404

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4585731/
https://www.ncbi.nlm.nih.gov/pubmed/26391180
http://dx.doi.org/10.1038/srep14404

Ejemplares similares